Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare and ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $30.00. The company’s shares ...

1 Day TEVA 0.63% DJIA 0.78% S&P 500 1.00% Health Care/Life Sciences 1527.34% ...

SAN FRANCISCO, Jan 16 (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for president-elect Donald Trump and Congress on ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days before the US government is set to release the next list of drugs selected for ...

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...